Company intelligence / Profile preview
Novomedison
Beijing, Beijing, Chinanovomedison.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novomedison is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative immune cell therapies for oncology. The company utilizes its proprietary i-CRT (Immune-Cell Reprogramming Technology) platform to engineer CAR-T and TCR-T products designed to overcome the immunosuppressive microenvironment of solid tumors. Its lead candidate, NM-002, is a GPC3-targeted CAR-T therapy currently undergoing clinical evaluation for patients with advanced hepatocellular carcinoma. Novomedison aims to improve the efficacy and persistence of cell therapies through advanced genetic engineering and immune cell modulation.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyT cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Novomedison.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novomedison.